Lyell Immunopharma, Inc. Common Stock
LYELLyell Immunopharma, Inc. is a biotechnology company focused on developing cell therapies to treat cancer. Founded with a focus on advancing T-cell engineering, Lyell aims to create durable and effective immune-based treatments by leveraging its proprietary platform technologies. The company's approach involves designing and manufacturing next-generation T-cell therapies to improve patient outcomes in oncology.
Company News
Century Therapeutics announced the appointments of Dr. Han Lee and Dr. Martin Murphy to its Board of Directors, bringing extensive experience in biotechnology, corporate development, and life science investment.
Lyell Immunopharma reported promising clinical trial results for ronde-cel, a CAR T-cell therapy targeting large B-cell lymphoma, showing high response rates and a manageable safety profile across multiple treatment lines.
Lyell Immunopharma presented clinical trial data for ronde-cel, a dual-targeting CD19/CD20 CAR T-cell therapy for aggressive large B-cell lymphoma, highlighting promising response rates and safety profile at the 67th ASH Annual Meeting.
Several biotech companies are developing innovative cancer treatments, with promising clinical trial results in various cancer types, focusing on immunotherapy and personalized medicine approaches.
Lyell Immunopharma announced positive clinical data for its lead product candidate LYL314, an autologous dual-targeting CD19/CD20 CAR T-cell therapy, in the treatment of relapsed and/or refractory large B-cell lymphoma. The data showed high rates of durable complete responses in patients treated in the third- or later-line setting.
